Interferon receptors during treatment of chronic hepatitis B with interferon.

Abstract

The in vitro binding of 125I-labelled human alpha-interferon to peripheral blood mononuclear cells from 13 patients with chronic hepatitis B during interferon therapy was assayed in order to identify changes in the number of interferon receptors during treatment. Nine patients were treated with human alpha-interferon (Hu alpha-IFN) or human beta-interferon (Hu beta-IFN) daily for 4 weeks. During therapy, receptor sites per cell decreased by 40%. Two weeks after therapy ceased, this number had returned to the pretreatment level. The other four patients were given Hu alpha-IFN daily for 2 weeks, no injections for 2 weeks, and daily injections for 2 weeks. During both periods of therapy, receptor sites decreased by 40%. The number increased to 94% of the pretreatment level 1 week after the first period and to 101% 2 weeks later. It was 80% 1 week after the second period of injections and 108% 2 weeks later.

• Authors: S Nakajima, T Kuroki, O Kurai, K Kobayashi, S Yamamoto
• Journal: Journal of gastroenterology and hepatology (J Gastroenterol Hepatol) 1989 Sep-Oct Vol. 4 Issue 5 Pg. 419-27 ISSN: 0815-9319 [Print] Australia
• PMID: 2485010 (Publication Type: Journal Article)

Chemical References

• Interferon Type I
• Interferon alpha-2
• Interferon-alpha
• Iodine Radioisotopes
• Receptors, Immunologic
• Receptors, Interferon
• Recombinant Proteins
• Interferons

Topics

• Adult
• Hepatitis B (metabolism, therapy)
• Humans
• Interferon Type I (administration & dosage, therapeutic use)
• Interferon alpha-2
• Interferon-alpha (administration & dosage, therapeutic use)
• Interferons (analysis)
• Iodine Radioisotopes
• Leukocytes, Mononuclear (chemistry)
• Male
• Receptors, Immunologic (analysis)
• Receptors, Interferon
• Recombinant Proteins